1 Ocak 2018 Dergi makalesi Açık Erişim

Yuksel, Melike; Biberoglu, Kevser; Onder, Seda; Akbulut, K. Gonca; Tacal, Ozden

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 37007, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Sch Pharm, Dept Biochem, TR-06100 Ankara, Turkey", 
      "name": "Yuksel, Melike"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Sch Pharm, Dept Biochem, TR-06100 Ankara, Turkey", 
      "name": "Biberoglu, Kevser"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Sch Pharm, Dept Biochem, TR-06100 Ankara, Turkey", 
      "name": "Onder, Seda"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Gazi Univ, Sch Med, Dept Physiol, Ankara, Turkey", 
      "name": "Akbulut, K. Gonca"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Hacettepe Univ, Sch Pharm, Dept Biochem, TR-06100 Ankara, Turkey", 
      "name": "Tacal, Ozden"
    }
  ], 
  "datePublished": "2018-01-01", 
  "description": "Recently, we have demonstrated that toluidine blue O (TBO), a phenothiazine dye, shows inhibitory effects on both cholinesterases and amyloid pathology in Alzheimer's disease (AD) cellular model. In the present study, we aimed to determine the effects of TBO (in a purity of 85%) on amyloid and tau pathologies in a triple transgenic mouse model of AD (3xTg-AD). Beginning at 7.5 (mild pathology) or 13 (severe pathology) months of age, 3xTg-AD mice were treated intraperitoneally with 4mg/kg TBO or vehicle daily for 30 days. TBO treatment significantly reduced the levels of insoluble A beta 40 and A beta 42 in the hippocampi of mild and severe pathology groups compared to vehicle-treated counterparts. When the levels of full-length amyloid precursor protein (APP) and beta-site APP-cleaving enzyme 1 (BACE1) were assessed in 3xTg-AD mice at late pathological stage, no significant changes were observed after TBO treatment. Similarly, TBO did not recover hyperphosphorylation of tau at residues Thr181 and Ser202/Thr205 significantly in soluble and insoluble hippocampal fractions of 3xTg-AD mice. Taken together, the current study is the first in vivo report, to our knowledge, demonstrating that TBO mitigates amyloid pathology in 3xTg-AD mice with no apparent change on tau phosphorylation. Overall, the preliminary data presented here support the possible use of TBO as a disease-modifying drug for AD treatment. (C) 2017 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.", 
  "headline": "Toluidine blue O modifies hippocampal amyloid pathology in a transgenic mouse model of Alzheimer's disease", 
  "identifier": 37007, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Toluidine blue O modifies hippocampal amyloid pathology in a transgenic mouse model of Alzheimer's disease", 
  "url": "https://aperta.ulakbim.gov.tr/record/37007"
}